• Lessons learned from adverse events and reactions inform donor care standards and practices and are reflected in the WMDA Standards.

• The experiences and needs of donors are understood and communicated and reflected in donor care standards.

• WMDA is recognised as a global advocate for donor care.
• Transplant centre staff, working with donors, have access to high-quality training.
• WMDA members adopt standards, protocols and procedures that safeguard the rights and safety of donors.
• National and international authorities support stem cell donation and recognise donor care standards.  

What will WMDA and its members do?

• Update and promote donor care standards that reflect evidence, best practice and ethical considerations.
  Examples: make standards relevant to both related and unrelated donors; triennial review of mobilising agents guidelines (G-CSF)
  Example: develop and maintain guidelines in relation to donor consent/counselling

• Collect, analyse and report data relating to adverse events and reactions and share insight with members and regulatory authorities. Example: roll out new and improved online SEAR/SPEAR reporting system for both related and unrelated adverse events and reactions

• Improve, maintain and promote WMDA’s Donor Medical Suitability Wiki. Example:respond to infectious diseases outbreaks (e.g. Zika); expand Wiki to include the screening of cord blood donors.
• In collaboration with transplant societies ensure that a professional training programme for transplant centre staff working with donors is available.

• Help WMDA members to inform and influence national and international authorities and other stakeholders (e.g. WBMT EBMT), so that voluntary stem cell donation and donor care is supported.
• Celebrate the contribution made by donors.
  Example: World Marrow Donor Day
•  Explore the role of WMDA in relation to research involving donors Example: develop ethical principles and guidelines and explore possibility to maintain a register of donor research dissemination research findings.

• WMDA is an important stakeholder in the growth of novel cellular therapies, focusing on safeguarding the well-being of donors.
• WMDA is using the collective voice of its members to advocate for the interests of donors and registries in regulation and policy where donor care and the international exchange of cellular products is concerned.

• WMDA will be giving its members insight, evidence and best practice to safeguard the safety and well-being of donors in all steps related to the donation.

• WMDA is globally known as the trusted repository for serious adverse events reporting.